Hospital Acquired Infection Testing Market: By Product (Sterilant, Disinfectants, and Other Products), By Infection type (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections, and Other Indications), By End User (Hospitals and Intensive Care Units, Ambulatory Surgical and Diagnostic Centres, Nursing Homes, and Maternity Centres), and By Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Hospital Acquired Infection Testing Market was valued at USD 3,482.1 million in 2022 and is expected to grow at 7.6% CAGR during the forecast period. Hospital-acquired infection (HAI), also called nosocomial infection is caused by bacterial, fungal, and viral pathogens while receiving treatment in healthcare facilities. The high prevalence of these HAIs is expected to significantly drive the demand for its therapeutics and fuel market growth in the coming years. According to the report published by the Organisation for Economic Co-operation and Development (OECD) in 2018, annually around 3.8 million people in EU countries acquire a healthcare-associated infection in acute care hospitals. The same source also states that each year around 90,000 people in the EU countries die due to some type of HAIs. The high prevalence of HAI and increasing resistance to available antibiotics have significantly fuelled the demand for novel HAI therapeutics. Thus, major players in the market are involved in excessive R&D activities for the development of new HAI drugs and gaining their approval in major markets. For instance, in June 2019, the FDA approved an expanded indication of Merck & Co., Inc.’s drug Zerbaxa (ceftolozane and tazobactam), for the treatment of ventilator-associated bacterial pneumonia (HABP/VABP) and hospital-acquired bacterial pneumonia in patients 18 years and older. In recent decades, chronic diseases such as cancer, heart disease, diabetes, and arthritis have become major health issues with a rising prevalence globally. According to the data published by International Agency for Research on Cancer (IARC), the total number of new cancer cases was estimated to be around 18.1 million in 2018. The high prevalence of these chronic diseases has led to an increase in hospital admissions. For instance, according to the data published by the New York State Department of Health in November 2019, around 40% of adults in New York suffer from some type of chronic disease, which leads to around 23% of all hospitalizations. Thus, increasing hospitalizations due to the rising prevalence of chronic diseases is anticipated to result in higher cases of HAIs, aiding the growth of the market for HAIs therapeutics. In the recent past, there has been a significant decrease in the prevalence of HAIs in developing economies. Developed countries such as the USA, UK, and Germany are actively engaged in HAI preventive practices. Thus, the declining demand for HAI therapeutics in developed countries with increasing precautionary measures is anticipated to hinder the market growth.

Hospital-Acquired Infection Testing Market Key Developments:

  • In November 2020, Sonoma Pharmaceuticals, Inc. and the MicroSafe Group DMCC reported that the COVID-19 list of disinfectants, kept by the United States Environmental Protection Agency's List N, now includes Nanocyn hospital-grade disinfectant.
  • In November 2020, Innovative disinfectants Sani-24 Germicidal Disposable Wipe, Sani-HyPerCide Germicidal Disposable Wipe, and Sani-HyPerCide Germicidal Spray were introduced by PDI in March 2022 to aid infection prevention specialists in the ongoing fight against COVID-19 and the rising number of hospital-acquired infections (HAIs).

Hospital Acquired Infection Testing Market Summary

Study Period


Base Year




Largest Market

Asia Pacific

Fastest Growing Market

North America
Hospital-Acquired Infection Testing Market Dynmaics

One of the key factors driving industry growth is the rising geriatric population base. The Advancing age of the geriatric population makes them more vulnerable and prone to diseases, also lack of sanitation leads to HAIs. Thus, increasing the demand for diagnosis and other aspects supporting industry growth is the growing demand for HAI diagnostics from middle and low-income countries such as India and Brazil, the development of technologically advanced diagnostic products, rising awareness among healthcare workers, and initiatives taken by governments to counter the prevalence of HAIs. However, the decreasing prevalence of nosocomial infections in developed countries owing to improved healthcare infrastructure and rising awareness are expected to restrict industry growth.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Hospital Acquired Infection Testing Market Segmentation

By Product Type
  • Sterilant
  • Disinfectant
  • Others
By Infection type
  • Hospital Acquired Pneumonia.
  • Bloodstream Infections.
  • Surgical Site Infections.
  • Gastrointestinal Infections.
  • Urinary Tract Infections.
  • Others.
By End User
  • Hospital and Intensive Care Units.
  • Ambulatory Surgical and Diagnostic
  • Centres.
  • Nursing Homes.
  • Maternity Centres.
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The hospital-acquired infection testing market size was valued at USD 3,482.1 million in 2021 and is expected to grow at 7.6% CAGR during the forecast period.

The leading players in the global hospital-acquired infection testing market are Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Limited, AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Allergan Plc., Life Technologies, Diatherix laboratories, Qiagen GmbH, Meridian Biosciences, Nordion, Roche, Cantel Medical Corporation, Cepheid

Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and forecast presented from 2023 – 2029.

Merck & Co., Inc.
Pfizer Inc.
Bayer AG
GlaxoSmithKline Plc.
Daiichi Sankyo Company, Limited
AbbVie Inc.
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Allergan Plc.
Life Technologies
Diatherix laboratories
Qiagen GmbH
Meridian Biosciences
Cantel Medical Corporation